SkinBioTherapeutics plc, a life science company, engages in the research and development of lysates derived from the human microbiome on skin. It is developing pre-clinical product application, SkinBiotix, a cosmetic cream for skin health, as well as for applications in infection control and eczema. The company was formerly known as Skinbiotix Ltd. SkinBioTherapeutics plc was founded in 2016 and is based in Macclesfield, the United Kingdom.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+44-161-4682760
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees6
Next Earnings DateN/A
OptionableNot Optionable
Skinbiotherapeutics (LON:SBTX) Frequently Asked Questions
What is Skinbiotherapeutics' stock symbol?
Skinbiotherapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SBTX."
Has Skinbiotherapeutics been receiving favorable news coverage?
News articles about SBTX stock have trended neutral recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Skinbiotherapeutics earned a news impact score of 0.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Skinbiotherapeutics.
Who are some of Skinbiotherapeutics' key competitors?
Some companies that are related to Skinbiotherapeutics include Medlab Clinical (MDC), OncoCyte (OCX), Oxford Biodynamics (OBD), OncoCyte (OCX), Helix Biopharma (HBP), IntelGenx Technologies (IGX), Imugene (IMU), 4d Pharma (DDDD), Orthocell (OCC), Pediapharm (PDP), Ampio Pharmaceuticals (AMPE), Equillium (EQ), Circassia Pharmaceuticals (CIR), Medicure (MPH) and Orgenesis (ORGS).
What other stocks do shareholders of Skinbiotherapeutics own?
Who are Skinbiotherapeutics' key executives?
Skinbiotherapeutics' management team includes the folowing people:
- Dr. Catherine O'Neill, CEO, Chief Scientific Officer & Director
- Mr. Douglas John Quinn, CFO, Company Sec. & Director
- Mr. Stuart John Ashman, Exec. Director (Age 52)
How do I buy shares of Skinbiotherapeutics?
Shares of SBTX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Skinbiotherapeutics' stock price today?
One share of SBTX stock can currently be purchased for approximately GBX 18.30.
How big of a company is Skinbiotherapeutics?
What is Skinbiotherapeutics' official website?
How can I contact Skinbiotherapeutics?
Skinbiotherapeutics' mailing address is 15 1 Silk House, Park Green, MACCLESFIELD, SK11 7QJ, United Kingdom. The company can be reached via phone at +44-161-4682760.
MarketBeat Community Rating for Skinbiotherapeutics (LON SBTX)
MarketBeat's community ratings are surveys of what our community members think about Skinbiotherapeutics and other stocks. Vote "Outperform" if you believe SBTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
